# Biogen Expands Gene Therapy Manufacturing With 2 Billion Dollar Push as JPMorgan Upgrades Stock

- URL: https://stocks.freetheai.org/news/biogen-expands-gene-therapy-manufacturing-with-2-billion-dollar-push-as-jpmorgan-651b0c
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:BIIB](https://stocks.freetheai.org/symbols/NASDAQ-BIIB)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Biogen Inc. (BIIB) is committing 2 billion dollars toward an automated expansion of its gene-therapy manufacturing in North Carolina. The investment will increase total production capacity and grow the company footprint in the state to eight facilities. In tandem with the expansion plans, JPMorgan Chase upgraded the biotechnology company stock rating to Overweight.

The move reflects a significant push to bolster gene-therapy output and efficiency through state-of-the-art automation. Following the positive rating change from JPMorgan, shares of Biogen Inc. experienced an upward move, trading up 3.33 percent to 225.70 USD.

Investors will monitor how the added capacity and facility development progress in North Carolina, along with future clinical and commercial milestones across the company gene-therapy pipeline.

## Key points

- Biogen Inc. (BIIB) announced a 2 billion dollar expansion plan to enhance gene-therapy manufacturing in North Carolina.
- The investment will scale up automation and raise the company state footprint to eight total facilities.
- JPMorgan Chase upgraded Biogen Inc. stock to an Overweight rating.
- Biogen Inc. shares gained 3.33 percent to trade at 225.70 USD following the upgrade.

## Questions and answers

### Why did Biogen stock go up?

Biogen Inc. stock rose after JPMorgan Chase upgraded the company rating to Overweight and Biogen announced a 2 billion dollar gene-therapy expansion in North Carolina.

### How much is Biogen investing in North Carolina?

Biogen Inc. is investing 2 billion dollars to expand automated gene-therapy manufacturing, increasing its footprint in the state to eight facilities.

### What rating did JPMorgan give Biogen Inc.?

JPMorgan Chase upgraded Biogen Inc. to an Overweight rating.